Join us at ASCO 2024. Learn more

2024 American Society of Breast Surgeons Conference

Marriott Orlando World Center, Orlando, Florida
April 10-14, 2024

Join us for an Evening Symposium:

Unlocking Tomorrow's Care: The Power of Germline, Oncotype DX®, and Molecular Residual Disease (MRD) Testing in Shaping Personalized Breast Cancer Care

Wednesday, 4/10/2024, 7:00pm – 8:30pm ET
Location: Crystal J1 (Dinner will be provided)

Join speakers, Drs. Yao, Lipsyc-Sharf and Racz, as they review the expanded use of Oncotype DX Breast Recurrence Score® test in early-stage breast cancer patients, as well as the use of germline testing and molecular residual disease (MRD) in breast cancer patients.

Learning Objectives

  • Recognize the expanded use of the Oncotype DX Breast Recurrence Score® test for decision-making in the adjuvant setting beyond systemic therapy
  • Explore the rationale behind the recent ASCO recommendation for germline testing in breast cancer patients.
  • Discuss the evolving role of molecular residual disease (MRD) testing in breast cancer patients.
Katharine A. Yao, MS, MD

Vice Chair of Research, department of Surgery
Director, Breast Cancer Research Program
Program Director, Surgical Outcomes Research, Outcomes Research Network
NorthShore University Health System

Marla Lipsyc-Sharf, MD

Health Sciences Clinical Instructor of Medicine
Translational Oncology Research Laboratory of the Jonsson Comprehensive Cancer Center
University of California – Los Angeles

Jennifer Racz, MD

Director, Medical Affairs, Precision Oncology
Exact Sciences